Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Orthopedics

Skeletal Care & Orthopedics: Managing Fibrous Dysplasia

At a Glance

Fibrous dysplasia in McCune-Albright syndrome is managed by treating significant pain and stabilizing bones at risk of fracture. Many quiet lesions are monitored, while surgery addresses deformity or instability; sudden vision or function changes or a severe new headache need urgent evaluation.

Managing Fibrous Dysplasia (FD) requires a careful balance between medical treatment to manage symptoms and surgical intervention to maintain physical structure. Because FD replaces strong bone with weaker, fibrous tissue, the primary goals are to reduce pain and prevent life-altering fractures or deformities [1][2].

Medical Management of Bone Pain

Medications are used primarily to improve quality of life by targeting bone pain. They are not a “cure” for the underlying bone lesions [3].

  • IV Bisphosphonates: Drugs like pamidronate or zoledronate are the standard choice for persistent, moderate-to-severe bone pain [1]. They work by slowing down the cells that break down bone, which can lower “bone-turnover markers” in the blood. Observational evidence shows they can reduce pain in many patients [3][4].
    • Limitations: While they help with pain, research has not shown that bisphosphonates reliably prevent fractures or stop FD from spreading [5][6]. Kidney function, calcium, vitamin D, and dental health must be assessed before treatment.
    • Side Effects: Common side effects in children include a temporary “flu-like” reaction (fever and aches) after the first infusion and low calcium levels [5][7].
  • Denosumab: This is a potent medication used as an exceptional or investigational/rescue option for severe pain in expert bone-mineral centers [8].
    • Serious Risk: In children and adolescents, denosumab carries a risk of severe rebound hypercalcemia—a dangerous spike in blood calcium levels—and high bone turnover if the medication is stopped or delayed [9][10]. It should only be used with a clear “exit plan” before the first dose, and you should never start, stop, or postpone it without your treating specialist’s direct oversight [11].

Orthopedic Surgery: Stability First

Surgery in MAS is not meant to “remove” the FD, but rather to stabilize the bone. In most cases, if a lesion is not causing pain or at risk of breaking, “watchful waiting” (active surveillance) is the preferred approach [12][13].

  • Intramedullary Nailing: For long bones like the femur (thigh) or tibia (shin), the “gold standard” is a metal rod placed inside the center of the bone [14]. This rod acts as an internal splint that spans the entire length of the bone to prevent fractures [15].
  • Corrective Osteotomy: If a bone has already developed a significant deformity (like a “shepherd’s crook” hip), surgeons may perform an osteotomy—carefully cutting and realigning the bone—and securing it with a nail or plate [16][17].
  • What to Avoid: Simple “curettage and grafting” (scraping out the lesion and filling it with bone graft) is generally avoided in MAS. In younger patients, the FD often rapidly reabsorbs the new graft, causing the lesion to return [18][12].

Urgent Care: When to Seek Immediate Help

While most bone pain in MAS is chronic and manageable, certain symptoms require immediate medical evaluation rather than an outpatient clinic wait.

Warning Sign What it Could Mean Action Required
Rapidly Enlarging Mass A bone lesion that grows quickly and is accompanied by new, severe pain [19]. Prompt specialist evaluation for rare malignant transformation (such as osteosarcoma, which is extremely rare) or an aneurysmal bone cyst [20][21].
Changes in Vision Progressive new loss of vision, reduced color vision, double vision, or visual-field defect [22]. EMERGENCY ROOM or immediate specialist assessment for optic nerve compression in craniofacial FD [23].
Severe, New Headache A rapidly progressive headache, sometimes with severe vomiting or balance issues [24]. EMERGENCY ROOM for urgent neurologic evaluation for obstructive hydrocephalus (fluid buildup in the brain) [25].
Sudden Loss of Function Inability to bear weight on a leg or a sudden “crack” followed by sharp pain. EMERGENCY ROOM for immediate orthopedic evaluation for a pathologic fracture [26].

Note on Chronic Pain: Everyday aching, while difficult, is not an emergency. For persistent or worsening pain, prompt clinician contact is advised to determine if physical therapy, mobility aids, or medical adjustment is needed [26].

Common questions in this guide

When might fibrous dysplasia in McCune-Albright syndrome require surgery?
Surgery is usually considered when a bone is unstable, at high risk of fracture, or significantly deformed. Lesions that are not painful and do not threaten bone strength are often monitored instead of operated on.
Can pamidronate or zoledronate cure fibrous dysplasia?
Intravenous pamidronate or zoledronate may reduce persistent moderate-to-severe bone pain, but these medicines do not cure the bone lesions. They have not reliably been shown to prevent fractures or stop fibrous dysplasia from spreading, and kidney function, calcium, vitamin D, and dental health should be reviewed before treatment.
What operations are used to strengthen bones affected by fibrous dysplasia?
An intramedullary nail can act as an internal support across the length of a fragile femur or tibia. A corrective osteotomy may realign a severely bent bone, while simple scraping and bone grafting is often avoided in younger patients because the graft may be reabsorbed and the lesion can return.
What should I know before considering denosumab for bone pain?
Denosumab is generally reserved for exceptional or investigational use in severe pain under an expert bone-mineral specialist. In children and adolescents, stopping or delaying it can cause a dangerous rise in blood calcium and increased bone turnover, so a clear follow-up or stopping plan is needed before the first dose.
Which changes need emergency evaluation in McCune-Albright syndrome?
A sudden inability to bear weight, a crack followed by sharp pain, new vision loss or double vision, or a severe progressive headache with vomiting or balance problems needs immediate evaluation. A rapidly enlarging painful mass also requires prompt specialist assessment because it can signal a rare complication.
How can I tell whether new bone pain could represent a fracture?
A new sharp, localized pain or pain that appears with loss of function is more concerning than a familiar background ache. Inability to bear weight or a sudden crack followed by severe pain should be evaluated in an emergency setting, while persistent or worsening pain should be reported promptly to the care team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on McCune-Albright syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the location of my (or my child's) bone lesions, what is the 'impending fracture' risk, and are we at a point where surgery is safer than waiting?
  2. 2.Is my bone pain severe enough to warrant IV pamidronate, and what specific improvements in daily life should we look for to know if it's working?
  3. 3.If you recommend surgery for a femoral deformity, will you use an intramedullary nail that spans the entire bone to prevent future breaks below the hardware?
  4. 4.How often should I have an ophthalmology exam to screen for optic nerve pressure, and what baseline vision tests do we need?
  5. 5.Given the risk of rebound hypercalcemia, what is the long-term plan if we ever decide to use denosumab for bone pain?

References

References (26)
  1. 1

    Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.

    Javaid MK, Boyce A, Appelman-Dijkstra N, et al.

    Orphanet journal of rare diseases 2019; (14(1)):139 doi:10.1186/s13023-019-1102-9.

    PMID: 31196103
  2. 2

    Fibrous dysplasia of bone: craniofacial and dental implications.

    Burke AB, Collins MT, Boyce AM

    Oral diseases 2017; (23(6)):697-708 doi:10.1111/odi.12563.

    PMID: 27493082
  3. 3

    Bisphosphonates for the treatment of fibrous dysplasia of bone.

    Chapurlat R, Legrand MA

    Bone 2021; (143()):115784 doi:10.1016/j.bone.2020.115784.

    PMID: 33276154
  4. 4

    EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.

    Wang Y, Wang O, Jiang Y, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(1)):23-30 doi:10.4158/EP-2018-0328.

    PMID: 30383490
  5. 5

    Bisphosphonate therapy in pediatric fibrous dysplasia: A systematic review of clinical, biochemical, and radiological outcomes.

    Regmi A, Niraula BB

    Journal of clinical orthopaedics and trauma 2025; (70()):103182 doi:10.1016/j.jcot.2025.103182.

    PMID: 40934056
  6. 6

    Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.

    Florenzano P, Pan KS, Brown SM, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2019; (34(4)):653-660 doi:10.1002/jbmr.3649.

    PMID: 30645769
  7. 7

    Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome.

    Tessaris D, Matarazzo P, Lala R, Defabianis P

    Journal of pediatric endocrinology & metabolism : JPEM 2016; (29(3)):333-6.

    PMID: 26565547
  8. 8

    Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study.

    Ouyang Q, Jiajue R, Zhou R, et al.

    Frontiers in endocrinology 2026; (17()):1762370 doi:10.3389/fendo.2026.1762370.

    PMID: 41788765
  9. 9

    Individualized antiresorptive therapy in fibrous dysplasia and McCune-Albright syndrome: A retrospective cohort study.

    Lipkow T, Bartosik M, Sprick-Schütte J, et al.

    Bone reports 2026; (30()):101933 doi:10.1016/j.bonr.2026.101933.

    PMID: 42383208
  10. 10

    Efficacy of Denosumab for Treatment of Pain in Fibrous Dysplasia and McCune-Albright Syndrome: A Systematic Review.

    Yau V, Best DL

    Clinical endocrinology 2026; (105(2)):141-150 doi:10.1111/cen.70133.

    PMID: 41858142
  11. 11

    Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.

    Vanderniet JA, Szymczuk V, Högler W, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(5)):1371-1382 doi:10.1210/clinem/dgad657.

    PMID: 38041865
  12. 12

    Surgical treatment of monostotic fibrous dysplasia of the proximal femur in children and adolescents: Observational European Paediatric Orthopaedic Society multicenter study.

    van Geloven TP, de Witte PB, Laitinen MK, et al.

    Journal of children's orthopaedics 2025; 18632521251355884 doi:10.1177/18632521251355884.

    PMID: 40726900
  13. 13

    Management Strategies of Fibrous Dysplasia Involving the Paranasal Sinus and the Adjacent Skull Base.

    Shi LL, Xiong P, Zhen HT

    Ear, nose, & throat journal 2025; (104(2)):85-92 doi:10.1177/01455613221088728.

    PMID: 35418265
  14. 14

    Lower-limb intramedullary nailing in patients with polyostotic fibrous dysplasia who had a previous unsuccessful treatment. A report of 48 cases.

    Ippolito E, Farsetti P, Caterini R, et al.

    Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 2023; (24(1)):35 doi:10.1186/s10195-023-00705-7.

    PMID: 37402946
  15. 15

    [Preliminary results of surgical treatment of fibrous dysplasia of proximal femur in children].

    Bian Z, Guo Y, Zhu ZH, et al.

    Zhonghua wai ke za zhi [Chinese journal of surgery] 2021; (59(9)):730-736 doi:10.3760/cma.j.cn112139-20210307-00113.

    PMID: 34404170
  16. 16

    Fibrous dysplasia: Clinical features, deformities, management, and outcomes.

    Karaca MO, Özyıldıran M, Kalem M, et al.

    Joint diseases and related surgery 2026; (37(2)):531-542.

    PMID: 41906848
  17. 17

    Individualized approach to the surgical management of fibrous dysplasia of the proximal femur.

    Majoor BCJ, Leithner A, van de Sande MAJ, et al.

    Orphanet journal of rare diseases 2018; (13(1)):72 doi:10.1186/s13023-018-0805-7.

    PMID: 29720212
  18. 18

    Bone-Grafting in Polyostotic Fibrous Dysplasia.

    Leet AI, Boyce AM, Ibrahim KA, et al.

    The Journal of bone and joint surgery. American volume 2016; (98(3)):211-9 doi:10.2106/JBJS.O.00547.

    PMID: 26842411
  19. 19

    Osteosarcomatous Transformation of Long-Standing Fibrous Dysplasia of the Maxilla.

    Schwind WN, Brereton CB, Carrau RL, Cho RI

    Ophthalmic plastic and reconstructive surgery 2026; (42(5)):e219-e223 doi:10.1097/IOP.0000000000003163.

    PMID: 41418276
  20. 20

    Frequency of spontaneous osteosarcomatous transformation of craniofacial fibrous dysplasia: a systematic review.

    Furmah P, Aminoshariae A, Mupparapu M, Syed AZ

    Oral surgery, oral medicine, oral pathology and oral radiology 2023; (135(5)):678-685 doi:10.1016/j.oooo.2022.12.007.

    PMID: 36828758
  21. 21

    [Malignancy of fibrous dysplasia of the calvarial bone in patient with McCune-Albright syndrome: clinical observation and literature review].

    Rakityanskiy MM, Vinogradov EV, Pronin IN, et al.

    Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko 2025; (89(4)):87-97 doi:10.17116/neiro20258904187.

    PMID: 40864539
  22. 22

    Craniofacial fibrous dysplasia: Systematic review of facial management.

    Bouet B, Schlund M, De Massary M, Nicot R

    Journal of stomatology, oral and maxillofacial surgery 2023; (124(6 Suppl 2)):101660 doi:10.1016/j.jormas.2023.101660.

    PMID: 37866506
  23. 23

    Optical Coherence Tomography in the Management of Skull Base Fibrous Dysplasia with Optic Nerve Involvement.

    Loewenstern J, Hernandez CM, Chadwick C, et al.

    World neurosurgery 2018; (109()):e546-e553 doi:10.1016/j.wneu.2017.10.018.

    PMID: 29038079
  24. 24

    Head and neck manifestations of an undiagnosed McCune-Albright syndrome: clinicopathological description and literature review.

    Lecumberri B, Pozo-Kreilinger JJ, Esteban I, et al.

    Virchows Archiv : an international journal of pathology 2018; (473(5)):645-648 doi:10.1007/s00428-018-2396-z.

    PMID: 29984378
  25. 25

    Craniofacial fibrous dysplasia: A 10-case series.

    Couturier A, Aumaître O, Gilain L, et al.

    European annals of otorhinolaryngology, head and neck diseases 2017; (134(4)):229-235 doi:10.1016/j.anorl.2017.02.004.

    PMID: 28302454
  26. 26

    A narrative review of the literature on the pediatric orthopedic management of fibrous dysplasia.

    Paris E, De Marco G, Vazquez O, et al.

    Frontiers in pediatrics 2024; (12()):1502262 doi:10.3389/fped.2024.1502262.

    PMID: 39981406

This page is for informational purposes only and does not constitute medical advice. Your orthopedic and bone-mineral specialists should guide treatment, medication, surgery, and urgent evaluation for you or your child.